Ticker LaunchIPO · SGP
SpyGlass Pharma, Inc.
Formerly SpyGlassPharma, Inc.; SpyGlass Ophthalmics, Inc.
SpyGlass Pharma, Inc. (SGP) priced its initial public offering on Feb 6, 2026 at $16.00 per share, within its $15.00–$17.00 range, raising $150M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $510.6M. Jefferies was lead-left underwriter, joined by Leerink Partners, Citigroup and Stifel. Wilson Sonsini advised the company and Latham & Watkins advised the underwriters.
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company developing long-acting, sustained drug delivery for chronic eye conditions. Its lead candidate, the Bimatoprost Drug Pad-IOL System, uses drug pads placed with an intraocular lens.
- Status
- IPO
- Ticker
- SGP
- Exchange
- Nasdaq Global Select
- Priced
- Feb 6, 2026
- IPO price
- $16.00
- Price range
- $15.00–$17.00
- Raised
- $150M
- Market cap at IPO price
- $510.6M
- First filed
- Jan 16, 2026
- Underwriters
- Jefferies, Leerink Partners, Citigroup and Stifel
- Company counsel
- Wilson Sonsini
- Underwriters' counsel
- Latham & Watkins
- Sector
- Healthcare
- Country / state
- CA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jan 16, 2026
- Latest amendment Jan 29, 2026
- Final prospectus (424B4) Feb 6, 2026
- All filings on EDGAR CIK 1778922
Other Healthcare IPOs in 2026
- Mobia Medical, Inc.MOBI · May 8, 2026 · $150M
- MiniMed Group, Inc.MMED · Mar 6, 2026 · $560M